Toxidromes

Critical Care Clinics

Volumn 28, Issue 4, 2012, Pages 479-498

  Holstege, Christopher P ^a   Borek, Heather A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Poisoning; Syndrome; Toxicology; Toxidrome

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ARSENIC TRIOXIDE; BEPRIDIL; CHLOROQUINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CITALOPRAM; CLARITHROMYCIN; ERYTHROMYCIN; HALOFANTRINE; HYDROXYCHLOROQUINE; LEVACETYLMETHADOL; METHADONE; NEUROLEPTIC AGENT; OPIATE; PENTAMIDINE; QUININE; QUINOLONE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT; TACROLIMUS; VENLAFAXINE;

AGITATION; ANHIDROSIS; ANION GAP; ANTICHOLINERGIC SYNDROME; BRADYCARDIA; BRONCHOSPASM; CHOLINERGIC TOXIDROME; DELIRIUM; DIAPHORESIS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG SCREENING; ELECTROCARDIOGRAM; GLASGOW COMA SCALE; HALLUCINATION; HUMAN; HYPERTENSION; HYPERTHERMIA; INTENSIVE CARE; INTESTINE SOUND; INTOXICATION; LACRIMATION; METABOLIC ACIDOSIS; MIOSIS; MYDRIASIS; OPIOID TOXIDROME; PHOTOPHOBIA; PRIORITY JOURNAL; QRS COMPLEX; QT PROLONGATION; REVIEW; SALIVATION; SEDATION; SYMPATHOMIMETIC TOXIDROME; TACHYCARDIA; TOXIDROME; URINE RETENTION; VOMITING;

ACID-BASE EQUILIBRIUM; ANALGESICS, OPIOID; BLOOD CHEMICAL ANALYSIS; CHOLINERGIC AGENTS; CHOLINERGIC ANTAGONISTS; CRITICAL CARE; ELECTROCARDIOGRAPHY; HUMANS; OSMOLAR CONCENTRATION; PHYSICAL EXAMINATION; POISONING; SYMPATHOMIMETICS; URINALYSIS;

EID: 84866485176     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2012.07.008     Document Type: Review

References (76)

1. Holstege C.P., Dobmeier S.G., Bechtel L.K. Critical care toxicology. Emerg Med Clin North Am 2008, 26(3):715-739.
2. Lawrence D.T., Bechtel L., Walsh J.P., et al. The evaluation and management of acute poisoning emergencies. Minerva Med 2007, 98(5):543-568.
3. Zimmerman J.L. Poisonings and overdoses in the intensive care unit: general and specific management issues. Crit Care Med 2003, 31(12):2794-2801.
4. Nice A., Leikin J.B., Maturen A., et al. Toxidrome recognition to improve efficiency of emergency urine drug screens. Ann Emerg Med 1988, 17(7):676-680.
5. Lin T.J., Nelson L.S., Tsai J.L., et al. Common toxidromes of plant poisonings in Taiwan. Clin Toxicol 2009, 47(2):161-168.
6. Boyle J.S., Bechtel L.K., Holstege C.P. Management of the critically poisoned patient. Scand J Trauma Resusc Emerg Med 2009, 17(1):29.
7. Erickson T.B., Thompson T.M., Lu J.J. The approach to the patient with an unknown overdose. Emerg Med Clin North Am 2007, 25(2):249-281.
8. Estelle F., Simons R. H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 1999, 83(5):481-488.
9. Scott J., Pache D., Keane G., et al. Prolonged anticholinergic delirium following antihistamine overdose. Australas Psychiatry 2007, 15(3):242-244.
10. Kwong T.C. Organophosphate pesticides: biochemistry and clinical toxicology. Ther Drug Monit 2002, 24(1):144-149.
11. Rusyniak D.E., Nanagas K.A. Organophosphate poisoning. Semin Neurol 2004, 24(2):197-204.
12. Hoffmann U., Papendorf T. Organophosphate poisonings with parathion and dimethoate. Intensive Care Med 2006, 32(3):464-468.
13. Eddleston M., Mohamed F., Davies J.O., et al. Respiratory failure in acute organophosphorus pesticide self-poisoning. QJM 2006, 99(8):513-522.
14. Hsieh B.H., Deng J.F., Ger J., et al. Acetylcholinesterase inhibition and the extrapyramidal syndrome: a review of the neurotoxicity of organophosphate. Neurotoxicology 2001, 22(4):423-427.
15. Aygun D. Diagnosis in an acute organophosphate poisoning: report of three interesting cases and review of the literature. Eur J Emerg Med 2004, 11(1):55-58.
16. Medicis J.J., Stork C.M., Howland M.A., et al. Pharmacokinetics following a loading plus a continuous infusion of pralidoxime compared with the traditional short infusion regimen in human volunteers. J Toxicol Clin Toxicol 1996, 34(3):289-295.
17. Beaule P.E., Smith M.I., Nguyen V.N. Meperidine-induced seizure after revision hip arthroplasty. J Arthroplasty 2004, 19(4):516-519.
18. Spiller H.A., Villalobos D., Krenzelok E.P., et al. Prospective multicenter study of sulfonylurea ingestion in children. J Pediatr 1997, 131(1 Pt 1):141-146.
19. Stork C.M., Redd J.T., Fine K., et al. Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate-a case report. J Toxicol Clin Toxicol 1995, 33(2):179-183.
20. Gillman P.K. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005, 95(4):434-441.
21. Centers for Disease Control and Prevention (CDC) Atypical reactions associated with heroin use-five states, January-April 2005. MMWR Morb Mortal Wkly Rep 2005, 54(32):793-796.
22. Rusyniak D.E., Sprague J.E. Hyperthermic syndromes induced by toxins. Clin Lab Med 2006, 26(1):165-184.
23. Jaehne E.J., Salem A., Irvine R.J. Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia. Psychopharmacology (Berl) 2007, 194(1):41-52.
24. Katz K.D., Curry S.C., Brooks D.E., et al. The effect of cyclosporine A on survival time in salicylate-poisoned rats. J Emerg Med 2004, 26(2):151-155.
25. Isbister G.K., Buckley N.A., Whyte I.M. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 2007, 187(6):361-365.
26. Seitz D.P., Gill S.S. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. Psychosomatics 2009, 50(1):8-15.
27. Stowell K.M. Malignant hyperthermia: a pharmacogenetic disorder. Pharmacogenomics 2008, 9(11):1657-1672.
28. Kruse J.A., Cadnapaphornchai P. The serum osmole gap. J Crit Care 1994, 9(3):185-197.
29. Erstad B.L. Osmolality and osmolarity: narrowing the terminology gap. Pharmacotherapy 2003, 23(9):1085-1086.
30. Glaser D.S. Utility of the serum osmol gap in the diagnosis of methanol or ethylene glycol ingestion. Ann Emerg Med 1996, 27(3):343-346.
31. Worthley L.I., Guerin M., Pain R.W. For calculating osmolality, the simplest formula is the best. Anaesth Intensive Care 1987, 15(2):199-202.
32. Suchard J.R. Osmolal gap. Medical toxicology 2004, 106-109. Lippincott Williams & Wilkins, Philadelphia. 3rd edition. R.C. Dart, E.M. Caravati, I.M. White (Eds.).
33. Smithline N., Gardner K.D. Gaps-anionic and osmolal. JAMA 1976, 236(14):1594-1597.
34. Glasser L., Sternglanz P.D., Combie J., et al. Serum osmolality and its applicability to drug overdose. Am J Clin Pathol 1973, 60(5):695-699.
35. McQuillen K.K., Anderson A.C. Osmol gaps in the pediatric population. Acad Emerg Med 1999, 6(1):27-30.
36. Aabakken L., Johansen K.S., Rydningen E.B., et al. Osmolal and anion gaps in patients admitted to an emergency medical department. Hum Exp Toxicol 1994, 13(2):131-134.
37. Darchy B., Abruzzese L., Pitiot O., et al. Delayed admission for ethylene glycol poisoning: lack of elevated serum osmol gap. Intensive Care Med 1999, 25(8):859-861.
38. Hoffman R.S., Smilkstein M.J., Howland M.A., et al. Osmol gaps revisited: normal values and limitations. J Toxicol Clin Toxicol 1993, 31(1):81-93.
39. Eder A.F., McGrath C.M., Dowdy Y.G., et al. Ethylene glycol poisoning: toxicokinetic and analytical factors affecting laboratory diagnosis. Clin Chem 1998, 44(1):168-177.
40. Steinhart B. Case report: severe ethylene glycol intoxication with normal osmolal gap-" a chilling thought." J Emerg Med 1990, 8(5):583-585.
41. Chabali R. Diagnostic use of anion and osmolal gaps in pediatric emergency medicine. Pediatr Emerg Care 1997, 13(3):204-210.
42. Ishihara K., Szerlip H.M. Anion gap acidosis. Semin Nephrol 1998, 18(1):83-97.
43. Gabow P.A. Disorders associated with an altered anion gap. Kidney Int 1985, 27(2):472-483.
44. Judge B.S. Metabolic acidosis: differentiating the causes in the poisoned patient. Med Clin North Am 2005, 89(6):1107-1124.
45. Wells K., Williamson M., Holstege C.P., et al. The association of cardiovascular toxins and electrocardiographic abnormality in poisoned patients. Am J Emerg Med 2008, 26(8):957-959.
46. Anderson M.E., Al-Khatib S.M., Roden D.M., et al. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002, 144(5):769-781.
47. Sides G.D. QT interval prolongation as a biomarker for torsades de pointes and sudden death in drug development. Dis Markers 2002, 18(2):57-62.
48. Nelson L.S. Toxicologic myocardial sensitization. J Toxicol Clin Toxicol 2002, 40(7):867-879.
49. ECG in emergency medicine and acute care 2005, Elsevier-Mosby, Phildelphia. T.C. Chan, W.J. Brady, R.A. Harrigan (Eds.).
50. Yap Y.G., Camm A.J. Drug induced QT prolongation and torsades de pointes. Heart 2003, 89(11):1363-1372.
51. De Ponti F., Poluzzi E., Cavalli A., et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002, 25(4):263-286.
52. Priori S.G., Cantu F., Schwartz P.J. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology. Schweiz Med Wochenschr 1996, 126(41):1727-1731.
53. Kolecki P.F., Curry S.C. Poisoning by sodium channel blocking agents. Crit Care Clin 1997, 13(4):829-848.
54. Harrigan R.A., Brady W.J. ECG abnormalities in tricyclic antidepressant ingestion. Am J Emerg Med 1999, 17(4):387-393.
55. Heaney R.M. Left bundle branch block associated with propoxyphene hydrochloride poisoning. Ann Emerg Med 1983, 12(12):780-782.
56. Fernandez-Quero L., Riesgo M.J., Agusti S., et al. Left anterior hemiblock, complete right bundle branch block and sinus tachycardia in maprotiline poisoning. Intensive Care Med 1985, 11(4):220-222.
57. Brady W.J., Skiles J. Wide QRS complex tachycardia: ECG differential diagnosis. Am J Emerg Med 1999, 17(4):376-381.
58. Clark R.F., Vance M.V. Massive diphenhydramine poisoning resulting in a wide-complex tachycardia: successful treatment with sodium bicarbonate. Ann Emerg Med 1992, 21(3):318-321.
59. Joshi A.K., Sljapic T., Borghei H., et al. Case of polymorphic ventricular tachycardia in diphenhydramine poisoning. J Cardiovasc Electrophysiol 2004, 15(5):591-593.
60. Wolfe T.R., Caravati E.M., Rollins D.E. Terminal 40-ms frontal plane QRS axis as a marker for tricyclic antidepressant overdose. Ann Emerg Med 1989, 18(4):348-351.
61. Berkovitch M., Matsui D., Fogelman R., et al. Assessment of the terminal 40-millisecond QRS vector in children with a history of tricyclic antidepressant ingestion. Pediatr Emerg Care 1995, 11(2):75-77.
62. Zareba W., Moss A.J., Rosero S.Z., et al. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol 1997, 80(9):1168-1173.
63. Kerns W., Garvey L., Owens J. Cocaine-induced wide complex dysrhythmia. J Emerg Med 1997, 15(3):321-329.
64. Bania T.C., Blaufeux B., Hughes S., et al. Calcium and digoxin vs calcium alone for severe verapamil toxicity. Acad Emerg Med 2000, 7(10):1089-1096.
65. Dorsey S.T., Biblo L.A. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 2000, 18(2):227-229.
66. Kellermann A.L., Fihn S.D., LoGerfo J.P., et al. Impact of drug screening in suspected overdose. Ann Emerg Med 1987, 16(11):1206-1216.
67. Mahoney J.D., Gross P.L., Stern T.A., et al. Quantitative serum toxic screening in the management of suspected drug overdose. Am J Emerg Med 1990, 8(1):16-22.
68. Brett A. Toxicologic analysis in patients with drug overdose. Arch Intern Med 1988, 148(9):2077.
69. Bast R.P., Helmer S.D., Henson S.R., et al. Limited utility of routine drug screening in trauma patients. South Med J 2000, 93(4):397-399.
70. Fabbri A., Marchesini G., Morselli-Labate A.M., et al. Comprehensive drug screening in decision making of patients attending the emergency department for suspected drug overdose. Emerg Med J 2003, 20(1):25-28.
71. Milzman D.P., Boulanger B.R., Rodriguez A., et al. Pre-existing disease in trauma patients: a predictor of fate independent of age and injury severity score. J Trauma 1992, 32(2):236-243.
72. Perrone J., De Roos F., Jayaraman S., et al. Drug screening versus history in detection of substance use in ED psychiatric patients. Am J Emerg Med 2001, 19(1):49-51.
73. George S., Braithwaite R.A. A preliminary evaluation of five rapid detection kits for on site drugs of abuse screening. Addiction 1995, 90(2):227-232.
74. Sena S.F., Kazimi S., Wu A.H. False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine. Clin Chem 2002, 48(4):676-677.
75. Camara P.D., Audette L., Velletri K., et al. False-positive immunoassay results for urine benzodiazepine in patients receiving oxaprozin (Daypro). Clin Chem 1995, 41(1):115-116.
76. Schneider S., Wennig R. Interference of diphenhydramine with the EMIT II immunoassay for propoxyphene. J Anal Toxicol 1999, 23(7):637-638.